ValiRx Plc (LON:VAL) has recorded a “statistically significant dose-dependent response” for its VAL201 treatment in a Phase I/II clinical trial regarding its effect on prostate cancer.
The cancer therapeutics firm said participants in the trial treated with VAL201 displayed a “statistically significant correlation” for reductions over time in the amount of testosterone and prostate-specific antigen (PSA), both of which are commonly used markers for disease progression in prostate cancer.
READ: ValiRx enters final stages of phase I/II trial of its VAL201 prostate cancer drug
ValiRx added that the data had confirmed there were no significant adverse trends across liver or kidney function as a result of the VAL201 treatment, as well as “no impact on cardiac rhythm”.
Information from the clinical evaluation had also shown that ValiRx was addressing the protocol's primary and secondary endpoints - as well as all the exploratory tertiary endpoints.
The company entered the final stages of the Phase I/II trial in October, when it was given permission by UK regulators to up the dose it gave to patients after early feedback showed the drug was safe and well-tolerated.
Dr Satu Vainikka, chief executive of ValiRx, said the treatment was having “having a positive and desired effect on prostate cancer patients' disease markers”.
He added that the latest data showed “the more a patient takes VAL201, the more a patient's PSA will decrease".
The shares were up 29% at 1.55p in early deals.